Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 247.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: -5.63%
• EPS Growth: 28.29%
• Country: SG
• Employees: 107
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.03
• Shares Outstanding: 1,231,494,600
• 10 Day Avg. Volume: 138,640
• 30 Day Avg. Volume: 247,960
• PEG Ratio: 0.04
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 1.94
• P/FCF Ratio: -2.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: S$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by financial performance challenges, including high leverage and negative profitability. Technical analysis provides a neutral outlook, while poor valuation metrics further weigh down the score.

Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model

Company Description

Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.

How the Company Makes Money

The company generates revenue through multiple streams, including fees for medical services rendered, sales of diagnostic and health technology products, and subscriptions for telemedicine services. Key revenue streams include partnerships with hospitals and clinics that utilize its advanced medical technologies, as well as collaborations with pharmaceutical companies for clinical trials and research. Additionally, the company may benefit from government healthcare initiatives and funding aimed at improving healthcare access and technology adoption, further contributing to its earnings.

Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview

Summary

The company shows strong revenue growth but faces significant profitability challenges with negative net profit and EBIT margins. High leverage and negative returns on equity pose financial risks, despite improvements in free cash flow.

Income Statement

The company exhibits a strong revenue growth rate of 95.43% in the latest period, indicating a positive trajectory in sales. However, profitability remains a significant concern with negative net profit margins (-166.53%) and EBIT margins (-146.29%), suggesting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio of 1.05, indicating significant leverage which could pose financial risks. The return on equity is negative (-47.02%), reflecting poor profitability and returns for shareholders. The equity ratio stands at 44.61%, showing a moderate level of equity financing.

Cash Flow

The cash flow statement reveals a substantial free cash flow growth rate of 91.31%, which is a positive sign. However, the operating cash flow to net income ratio is negative (-0.62), indicating that the company is not generating sufficient cash from operations to cover its net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.71M	15.71M	16.65M	16.23M	13.81M	12.92M
Gross Profit	-8.52M	14.42M	15.36M	-2.60M	-4.31M	-2.32M
EBITDA	-11.04M	-11.08M	-13.42M	-10.78M	-8.02M	-3.06M
Net Income	-26.16M	-26.16M	-37.45M	-18.07M	-12.43M	-9.35M
Balance Sheet
Total Assets	124.71M	124.71M	138.76M	159.52M	174.36M	172.08M
Cash, Cash Equivalents and Short-Term Investments	2.84M	2.84M	3.16M	11.05M	15.84M	10.29M
Total Debt	58.21M	58.21M	46.10M	80.77M	87.30M	92.26M
Total Liabilities	69.07M	69.07M	57.01M	114.60M	120.31M	112.90M
Stockholders Equity	55.64M	55.64M	81.74M	44.93M	54.05M	59.18M
Cash Flow
Free Cash Flow	-11.08M	-10.78M	-14.80M	-19.89M	-11.26M	-9.72M
Operating Cash Flow	-10.93M	-10.63M	-14.26M	-5.45M	-7.15M	-4.26M
Investing Cash Flow	112.97K	113.13K	-263.72K	-1.45M	3.72M	-5.25M
Financing Cash Flow	10.50M	10.20M	6.64M	2.11M	9.18M	10.66M

Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.74 is Neutral, neither overbought nor oversold. The STOCH value of 4.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:9G2.

Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSL	―	$1.88B	29.15	6.20%	2.50%	8.90%	4.57%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9G2	―	―	―	-39.37%	―	-5.63%	28.29%

Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events

Singapore Institute of Advanced Medicine Secures SGX-ST Approval for New Share Listing

Singapore Institute of Advanced Medicine Holdings Ltd. has received approval from the SGX-ST for the listing and quotation of 169,474,000 new shares. This includes a debt conversion of 149,726,000 shares from Caterine Limited and a placement of 19,748,000 shares at S$0.035 each. The listing is subject to compliance with SGX-ST’s requirements, and the shares must be placed within seven market days. The SGX-ST has noted potential implications for substantial acquisitions or reverse takeovers if the company acquires assets from related parties.

Singapore Institute of Advanced Medicine Streamlines Decision-Making Process

The Singapore Institute of Advanced Medicine Holdings Ltd. has dissolved its Strategic Review Committee (SRC) as of August 8, 2025. The Board of Directors will now directly handle the functions and recommendations previously managed by the SRC to streamline decision-making and expedite the implementation of initiatives.